ARA320804 is an experimental peptide derived from erythropoietin that is designed to provide tissue protective and anti inflammatory effects without stimulating red blood cell production. Developed by Araim Pharmaceuticals, it belongs to a class of non hematopoietic erythropoietin mimetics created to separate the protective properties of erythropoietin from its role in increasing hemoglobin levels. Preclinical research suggests ARA320804 may help reduce inflammation, limit oxidative stress, and support cellular repair in conditions involving tissue injury or chronic inflammation, while potentially avoiding risks such as thrombosis that are associated with traditional erythropoietin therapies.